139 related articles for article (PubMed ID: 16250644)
41. Design, synthesis and biological evaluation of new 3-[(4-aryl)piperazin-1-yl]-1-arylpropane derivatives as potential antidepressants with a dual mode of action: serotonin reuptake inhibition and 5-HT1A receptor antagonism.
Oficialdegui AM; Martinez J; Pérez S; Heras B; Irurzun M; Palop JA; Tordera R; Lasheras B; del Río J; Monge A
Farmaco; 2000 May; 55(5):345-53. PubMed ID: 10983279
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and biological activity of piperazine and diazepane amides that are histamine H3 antagonists and serotonin reuptake inhibitors.
Ly KS; Letavic MA; Keith JM; Miller JM; Stocking EM; Barbier AJ; Bonaventure P; Lord B; Jiang X; Boggs JD; Dvorak L; Miller KL; Nepomuceno D; Wilson SJ; Carruthers NI
Bioorg Med Chem Lett; 2008 Jan; 18(1):39-43. PubMed ID: 18060777
[TBL] [Abstract][Full Text] [Related]
43. Dual 5-HT1A agonists and 5-HT re-uptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity.
Heinrich T; Böttcher H; Schiemann K; Hölzemann G; Schwarz M; Bartoszyk GD; van Amsterdam C; Greiner HE; Seyfried CA
Bioorg Med Chem; 2004 Sep; 12(18):4843-52. PubMed ID: 15336263
[TBL] [Abstract][Full Text] [Related]
44. Structure-activity relationships of a series of substituted benzamides: potent D2/5-HT2 antagonists and 5-HT1a agonists as neuroleptic agents.
Norman MH; Rigdon GC; Hall WR; Navas F
J Med Chem; 1996 Mar; 39(5):1172-88. PubMed ID: 8676355
[TBL] [Abstract][Full Text] [Related]
45. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
46. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
Maeda K; Sugino H; Akazawa H; Amada N; Shimada J; Futamura T; Yamashita H; Ito N; McQuade RD; Mørk A; Pehrson AL; Hentzer M; Nielsen V; Bundgaard C; Arnt J; Stensbøl TB; Kikuchi T
J Pharmacol Exp Ther; 2014 Sep; 350(3):589-604. PubMed ID: 24947465
[TBL] [Abstract][Full Text] [Related]
47. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
[TBL] [Abstract][Full Text] [Related]
48. Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia.
Yan Y; Zhou P; Rotella DP; Feenstra R; Kruse CG; Reinders JH; van der Neut M; Lai M; Zhang J; Kowal DM; Carrick T; Marquis KL; Pausch MH; Robichaud AJ
Bioorg Med Chem Lett; 2010 May; 20(9):2983-6. PubMed ID: 20347298
[TBL] [Abstract][Full Text] [Related]
49. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
[TBL] [Abstract][Full Text] [Related]
50. Synthesis and preliminary pharmacological investigations of 1-(1,2-dihydro-2-acenaphthylenyl)piperazine derivatives as potential atypical antipsychotic agents in mice.
Srinivas P; Subramanian AR; Brust P; Raghavan SA; Rangisetty JB; Gupta CN; Sridhar N; Veeranjaneyulu A; Parimoo P
Farmaco; 1999 Aug; 54(8):567-72. PubMed ID: 10510854
[TBL] [Abstract][Full Text] [Related]
51. Synthesis, docking and pharmacological evaluation of novel homo- and hetero-bis 3-piperazinylpropylindole derivatives at SERT and 5-HT1A receptor.
Pessoa-Mahana H; González-Lira C; Fierro A; Zapata-Torres G; Pessoa-Mahana CD; Ortiz-Severin J; Iturriaga-Vásquez P; Reyes-Parada M; Silva-Matus P; Saitz-Barría C; Araya-Maturana R
Bioorg Med Chem; 2013 Dec; 21(24):7604-11. PubMed ID: 24262884
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors.
Heinrich T; Böttcher H; Gericke R; Bartoszyk GD; Anzali S; Seyfried CA; Greiner HE; Van Amsterdam C
J Med Chem; 2004 Sep; 47(19):4684-92. PubMed ID: 15341484
[TBL] [Abstract][Full Text] [Related]
53. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
[TBL] [Abstract][Full Text] [Related]
54. Synthesis and pharmacological evaluation of new (indol-3-yl)alkylamides and alkylamines acting as potential serotonin uptake inhibitors.
Fouchard F; Menciu C; Duflos M; Le Baut G; Lambrey B; Mourgues M; Perrissoud D
Arzneimittelforschung; 1999 Feb; 49(2):96-105. PubMed ID: 10083976
[TBL] [Abstract][Full Text] [Related]
55. Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization.
Johnson M; Antonio T; Reith ME; Dutta AK
J Med Chem; 2012 Jun; 55(12):5826-40. PubMed ID: 22642365
[TBL] [Abstract][Full Text] [Related]
56. Synthesis, pharmacological and structural studies of 5-substituted-3-(1-arylmethyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as multi-target ligands of aminergic GPCRs.
Kondej M; Wróbel TM; Silva AG; Stępnicki P; Koszła O; Kędzierska E; Bartyzel A; Biała G; Matosiuk D; Loza MI; Castro M; Kaczor AA
Eur J Med Chem; 2019 Oct; 180():673-689. PubMed ID: 31357129
[TBL] [Abstract][Full Text] [Related]
57. New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.
Liao Y; Venhuis BJ; Rodenhuis N; Timmerman W; Wikström H; Meier E; Bartoszyk GD; Böttcher H; Seyfried CA; Sundell S
J Med Chem; 1999 Jun; 42(12):2235-44. PubMed ID: 10377229
[TBL] [Abstract][Full Text] [Related]
58. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
Auclair AL; Kleven MS; Besnard J; Depoortère R; Newman-Tancredi A
Neuropsychopharmacology; 2006 Sep; 31(9):1900-9. PubMed ID: 16421514
[TBL] [Abstract][Full Text] [Related]
59. 3,4-Dihydro-2H-benzoxazinones are 5-HT(1A) receptor antagonists with potent 5-HT reuptake inhibitory activity.
Atkinson PJ; Bromidge SM; Duxon MS; Gaster LM; Hadley MS; Hammond B; Johnson CN; Middlemiss DN; North SE; Price GW; Rami HK; Riley GJ; Scott CM; Shaw TE; Starr KR; Stemp G; Thewlis KM; Thomas DR; Thompson M; Vong AK; Watson JM
Bioorg Med Chem Lett; 2005 Feb; 15(3):737-41. PubMed ID: 15664848
[TBL] [Abstract][Full Text] [Related]
60. 3-(Piperazinylpropyl)indoles: selective, orally bioavailable h5-HT1D receptor agonists as potential antimigraine agents.
Chambers MS; Street LJ; Goodacre S; Hobbs SC; Hunt P; Jelley RA; Matassa VG; Reeve AJ; Sternfeld F; Beer MS; Stanton JA; Rathbone D; Watt AP; MacLeod AM
J Med Chem; 1999 Feb; 42(4):691-705. PubMed ID: 10052976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
